---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-228131"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2023-09-05T23:59:59+00:00"
generated_at: "2026-06-11T00:04:47.036229+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Mirum acquires Travere's bile acid products Cholbam and Chenodal for $210M upfront plus $235M milestones

## Summary
- Completed asset purchase of Cholbam and Chenodal from Travere for $210M cash at closing, with up to $235M in sales-based milestone payments.
- Funded acquisition via $210M PIPE at $26.25/share from investors including Frazier Life Sciences, Avidity Partners, BVF Partners.
- Products treat rare liver diseases: bile acid synthesis disorders, peroxisomal disorders; Chenodal in Phase 3 for cerebrotendinous xanthomatosis (CTX).
- Travere received $210M upfront and is eligible for additional milestones; Mirum expects near-term label expansion opportunity for CTX.
- Financial statements for the acquired business to be filed as an amendment to this 8-K within 71 days.

## SEC filing metadata
- accession: 0001193125-23-228131
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2023-09-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000119312523228131/0001193125-23-228131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000119312523228131/d522051d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-228131
- JSON: https://secwatch.observer/filing/0001193125-23-228131.json
- Plain text: https://secwatch.observer/filing/0001193125-23-228131.txt

## Key facts
- M&A Transactions
  Mirum Pharmaceuticals, Inc. completed an acquisition involving Travere Therapeutics, Inc. for an upfront purchase price of $210,000,000 in cash (closed 2023-08-31).
  - Action: acquisition
  - Counterparty: Travere Therapeutics, Inc.
  - Consideration: an upfront purchase price of $210,000,000 in cash
  - Closing: 2023-08-31
  source text: (the “Purchase Agreement”), dated July 16, 2023, by and between the Company and Travere. Under the terms of the Purchase Agreement, the Company paid an upfront purchase price of $210,000,000 in cash to Travere at the Asset Purchase Closing using cash and cash equivalents from the Company’s balance sheet. The Company may pay Travere up to $235,000,000 after the Asset
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312523228131/0001193125-23-228131-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.